Medical and Ethical Issues Cloud Plans to Clone for Therapy
By Andrew Pollack,
The New York Times
| 02. 13. 2004
In cloning human embryos and extracting universal stem cells,
scientists in South Korea have taken a big step toward a tantalizing
goal: growing tailor-made replacement tissues for people who are sick
or injured. Imagine new cardiac muscles to restore a heart after a
heart attack, insulin-producing cells for diabetics or neurons to stave
off Parkinson's disease.
But significant scientific
barriers lie between this accomplishment and any actual therapy,
experts said. Moreover, ethical objections have put such research
off-limits to some scientists - including the many in the United States
who rely on federal money - and lack of investment has felled many
companies trying to develop cell-replacement therapies.
The
South Korean work is a step toward what is called "therapeutic
cloning." The work so far is "proof of concept of cloning but it's not
therapeutic yet," said Dr. Steven A. Goldman, chief of the division of
cell and gene therapy at the University of Rochester Medical Center.
It
is likely to be several years before tissues derived this way could
even be tested in patients, he and other experts said...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...